drugset
Drugs / OPB-111077
last change Jan 2026 re-read 2 minutes ago

OPB-111077

Small molecule targets STAT3

Developed for
acute myeloid leukemia · cancer · hepatocellular carcinoma · refractory malignant neoplasm · relapsed/refractory diffuse large B-cell lymphoma
Investigated by
Otsuka Pharmaceutical Co., Ltd. · Korea Otsuka Pharmaceutical Co., Ltd. · Apices Soluciones S.L. · Hospital Universitario 12 de Octubre · National University Hospital, Singapore · Otsuka America Pharmaceutical
+3 more · Otsuka Pharmaceutical Development & Commercialization, Inc. · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Vivia Biotech

Trials 7 · a red edge is where a trial was stopped

today NCT04049825 · Ph 1 NCT03197714 · Ph 1 NCT03158324 · Ph 2 NCT03063944 · Ph 1 NCT02250170 · Ph 1 NCT01942083 · Ph 1 NCT01711034 · Ph 1
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT04049825 Nov 2019 → Mar 2025 relapsed/refractory diffuse large B-cell lymphoma Otsuka Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 1 NCT03197714 Sep 2017 → Mar 2020 acute myeloid leukemia Hospital Universitario 12 de Octubre Completed No outcome recorded
Phase 1 NCT03063944 Mar 2017 → Jan 2024 acute myeloid leukemia Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Completed No outcome recorded
Phase 1 NCT02250170 Oct 2014 → Mar 2019 cancer Korea Otsuka Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 1 NCT01942083 May 2013 → Jun 2016 hepatocellular carcinoma Korea Otsuka Pharmaceutical Co., Ltd. Terminated No outcome recorded
Phase 1 NCT01711034 Jun 2012 → Dec 2015 cancer Otsuka Pharmaceutical Development & Commercialization, Inc. Completed No outcome recorded
Phase 21 trial
Phase 2 NCT03158324 May 2017 → May 2020 refractory malignant neoplasm National University Hospital, Singapore Unknown No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as OPB-111077 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03158324 ↗
6

NCT04049825 ↗

NCT01711034 ↗

NCT03197714 ↗

NCT03063944 ↗

NCT02250170 ↗

NCT01942083 ↗
Action Inhibit “OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation” PMID 29511132 ↗ Mar 2018
Modality Small molecule “A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.” PMID 29511132 ↗ Mar 2018
Route Oral “Patients received oral OPB-111077 daily in 28-day cycles until loss of clinical benefit.” PMID 29511132 ↗ Mar 2018
Target STAT3 “OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation” PMID 29511132 ↗ Mar 2018